Sirona Biochem Appoints David Moore to Board of Directors
January 23 2014 - 3:19PM
Marketwired
Sirona Biochem Appoints David Moore to Board of Directors
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 23, 2014) -
Sirona Biochem Corp. (TSX-VENTURE:SBM)(OTCQX:SRBCF) announced today
the appointment of David Moore to its Board of Directors.
"We are very fortunate to have David Moore join us," said Neil
Belenkie, Chief Executive Officer of Sirona Biochem. "David's
previous experience and success in the USA leading many of the
tasks that we are about to undertake, are unique and invaluable
resources to Sirona's leadership team. With David on board, we gain
another level of confidence in our ability to execute our
strategy."
About David Moore
David joins the board of directors with significant biotech and
big pharma experience. David is currently Chief Commercial Officer
of Cempra, a clinical-stage pharmaceutical company focused on
developing antibacterials to meet critical medical needs. Prior to
joining Cempra, David was Chief Business Officer of Ocera
Therapeutics, a publicly traded clinical stage biotech focused in
advanced liver disease. Prior to Ocera, he was Chief Business
Officer of Tranzyme Pharma, a publicly traded clinical stage
biotech and macrocyclic discovery chemistry company which David and
the management team successfully merged with Ocera Therapeutics in
July 2013. David has participated in several rounds of corporate
financing, successfully negotiated multiple license deals for both
clinical stage products and pre-clinical compounds in addition to
the recent strategic merger process. David has an extensive
commercial background having spent over 15 years developing and
managing pharmaceutical commercial programs with the majority of
that time spent with Ortho-McNeil and Janssen divisions of Johnson
& Johnson. David received his B.Sc. in Biology from Towson
University and an M.B.A. from Lehigh University, and a second
graduate degree in Health Policy Excellence from Thomas Jefferson
University.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements.
Sirona Biochem Corp.Christopher
HoptonCFO1.604.282.6064chopton@sironabiochem.comwww.sironabiochem.com
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Dec 2024 to Jan 2025
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Jan 2024 to Jan 2025
